Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 11/20 | 0.65 |
| ▸ | SLC12A5 | Q9H2X9 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16498372 | 1.00 | FFAR2 (0.65) | FFAR2SLC12A5JAK2JAK3CYP1A2 | |
| SCHEMBL16498379 | 0.90 | FFAR2 (0.66) | FFAR2SLC12A5JAK2JAK3CYP1A2 | |
| SCHEMBL16498387 | 0.90 | FFAR2 (0.66) | FFAR2SLC12A5JAK2JAK3CYP1A2 | |
| SCHEMBL16498807 | 0.82 | FFAR2 (0.70) | FFAR2SLC12A5CYP1A2 | |
| SCHEMBL16498689 | 0.82 | FFAR2 (0.70) | FFAR2SLC12A5CYP1A2 | |
| SCHEMBL16498305 | 0.82 | FFAR2 (0.70) | FFAR2SLC12A5CYP1A2 | |
| SCHEMBL16498302 | 0.82 | FFAR2 (0.70) | FFAR2SLC12A5CYP1A2 | |
| SCHEMBL16498076 | 0.81 | FFAR2 (0.84) | FFAR2SLC12A5JAK2JAK3CYP1A2 | |
| SCHEMBL16498079 | 0.81 | FFAR2 (0.84) | FFAR2SLC12A5JAK2JAK3CYP1A2 | |
| SCHEMBL16498007 | 0.80 | FFAR2 (0.67) | FFAR2SLC12A5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011151434-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-12-08 | — | — | WO | claimed |
| WO-2011151434-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-12-08 | — | — | WO | disclosed |